 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12345678910111213...178179» |
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P2 trial, Combination therapy: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study (clinicaltrials.gov) - May 7, 2024
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial, Metastases: FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC (clinicaltrials.gov) - May 7, 2024
P2, N=62, Not yet recruiting, Sponsor: Changzhou No.2 People's Hospital
- | Yidafan (ivonescimab) / Akesobio, Summit Therap
New P2 trial: SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer (clinicaltrials.gov) - May 7, 2024
P2, N=50, Not yet recruiting, Sponsor: Hubei Cancer Hospital
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Retrospective data, Journal: Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer. (Pubmed Central) - May 6, 2024
The results of this study indicate that nab-paclitaxel-based concurrent radiotherapy is tolerable and effective, and can be considered an alternative to cisplatin chemotherapy.
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial: SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) (clinicaltrials.gov) - May 6, 2024
P2, N=51, Not yet recruiting, Sponsor: Hubei Cancer Hospital
- |||| Gavreto (pralsetinib) / Rigel
Trial completion date, Trial primary completion date, Metastases: AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 5, 2024
P3, N=223, Active, not recruiting, Sponsor: Hoffmann-La Roche
The results of this study indicate that nab-paclitaxel-based concurrent radiotherapy is tolerable and effective, and can be considered an alternative to cisplatin chemotherapy. Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
- | onvansertib (PCM-075) / Cardiff Oncology
New P2 trial, Combination therapy, Metastases: Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - May 3, 2024
P2, N=35, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- ||||| Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: INTEGRATEIIb: RegoNivo vs Standard of Care Chemotherapy in AGOC (clinicaltrials.gov) - May 3, 2024
P3, N=450, Active, not recruiting, Sponsor: Australasian Gastro-Intestinal Trials Group
Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025 Recruiting --> Active, not recruiting
- Tagrisso (osimertinib) / AstraZeneca, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
Phase classification, Metastases: TREBLE: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 1, 2024
P3, N=8, Terminated, Sponsor: EQRx International, Inc.
Recruiting --> Active, not recruiting Phase classification: P3b --> P3
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P1 trial, Metastases: CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (clinicaltrials.gov) - May 1, 2024
P1, N=20, Not yet recruiting, Sponsor: John Lenehan
- | Hansizhuang (serplulimab) / Fosun Pharma, Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - May 1, 2024
P2, N=37, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | Sulanda (surufatinib) / Hutchmed, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date, Metastases: Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 30, 2024
P1/2, N=83, Recruiting, Sponsor: Chinese PLA General Hospital
Phase classification: P3b --> P3 Trial primary completion date: Feb 2024 --> Jul 2024
- | Yidafan (ivonescimab) / Akesobio, Summit Therap
New P2 trial: Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 30, 2024
P2, N=44, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- | New P3 trial, Liquid biopsy, Surgery, Circulating tumor DNA, Biopsy: LIQUIPANC: Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery (clinicaltrials.gov) - Apr 29, 2024
P3, N=100, Recruiting, Sponsor: Elisabethinen Hospital
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P1/2 trial, Metastases: Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer (clinicaltrials.gov) - Apr 29, 2024
P1/2, N=20, Recruiting, Sponsor: RenJi Hospital
- | albumin-bound paclitaxel / Generic mfg.
Journal: Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking. (Pubmed Central) - Apr 29, 2024
Trial primary completion date: Feb 2024 --> Jul 2024 In addition, in vitro gel filtration analysis and dialysis study demonstrated that PTX-loaded BSA nanoparticles had higher colloidal stability and sustained PTX release property than Abraxane
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Halaven (eribulin mesylate) / Eisai
New P2 trial, Combination therapy, Metastases: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer (clinicaltrials.gov) - Apr 29, 2024
P2, N=74, Recruiting, Sponsor: Fudan University
- |||| Tecentriq (atezolizumab) / Roche
New P2 trial, Metastases: EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 29, 2024
P2, N=76, Recruiting, Sponsor: NovoCure GmbH
- | Hansizhuang (serplulimab) / Fosun Pharma
New P4 trial: Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 28, 2024
P4, N=80, Not yet recruiting, Sponsor: Yang Jianjun, PhD
- | albumin-bound paclitaxel / Generic mfg.
Journal: IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis. (Pubmed Central) - Apr 26, 2024
IL4R-Abx accumulated at tumors, heightened immune-stimulatory cells while reducing immune-suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy.
- |||| tinengotinib (TT-00420) / TransThera Biosci
Trial completion, Combination therapy, Monotherapy, Metastases: Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 26, 2024
P1/2, N=203, Completed, Sponsor: TransThera Sciences (Nanjing), Inc.
These results indicate that IL4R-targeting allows enhancement of M2-macrophage shaping into M1-like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy. Active, not recruiting --> Completed
- | Cyramza (ramucirumab) / Eli Lilly
Journal, Metastases: Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01). (Pubmed Central) - Apr 25, 2024
P4
Ethics approval has been obtained from the Ethics Committee at the First Affiliated Hospital (Xijing Hospital) of Air force Military Medical University (KY20232220-F-1). This trial has been registered at the ClinicalTrials.gov: NCT06169410 (registration date: December 5, 2023).
- || ProAgio / ProDa BioTech
Enrollment open, Trial initiation date, Combination therapy, Metastases: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - Apr 25, 2024
P1, N=28, Recruiting, Sponsor: ProDa BioTech, LLC
This trial has been registered at the ClinicalTrials.gov: NCT06169410 (registration date: December 5, 2023). Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Sep 2023
- | Trial primary completion date: PARC: Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Apr 25, 2024
P=N/A, N=10, Recruiting, Sponsor: EBG MedAustron GmbH
Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Sep 2023 Trial primary completion date: Dec 2023 --> Dec 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy: Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. (clinicaltrials.gov) - Apr 25, 2024
P3, N=90, Recruiting, Sponsor: XIANG YANQUN
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6902;
Since the and PRODIGE and MPACT trials, FFX, GnP, or gemcitabine monotherapy have been the primary recommended 1L treatments for most pts with mPDAC. While recent years have seen an increase in the availability of targeted and CPI therapies appropriate for small subgroups of mPDAC pts, in a RW sample, almost all pts received one of the three standard therapies.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6899;
P2
Neoadjuvant camrelizumab combined with chemotherapy for NSCLC patients show promising pathological response rates and tolerable safety. Clinical trial information: NCT06241807.
- Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6898;
The burden of AEs was higher among the RW GnP cohort than the RW FFX cohort. G-CSF was more prevalent and began earlier in the FFX cohort, indicating prophylactic use.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Experience of seven Spanish centres with echoendoscopically implanted 32 P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6884;
Patients after 32P injection achieve long overall survival. Our ongoing prospective registry will allow evaluation of the oncological outcomes of this therapy at longer follow-up times.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical efficacy and safety of mTOR inhibitor in patients with advanced unresectable epithelioid hemangioendothelioma (EHE). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6798;
At present, there is no standard treatment for EHE, we can roughly see the efficacy of mTOR inhibitor everolimus in some EHE patients, mainly disease stability. Emphasis on side effect management, improve tolerance, and systematic treatment of EHE needs to be further explored.
- seviteronel (INO-464) / Innocrin
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6788;
P1b
5mg dexamethasone in combination with docetaxel or nab-paclitaxel chemotherapy. The combination is well tolerated with early efficacy signals.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6770;
Inetetamab combined with pyrotinib plus albumin-bound paclitaxel might be the most effective combination therapies. All AEs were controllable and tolerable.
- Tecentriq (atezolizumab) / Roche
Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6736;
P2
9 months) or the historical median OS of 5 months. Additional novel treatment strategies for patients with non-BRAF mutated ATC are warranted, especially when antiangiogenic drugs are contra-indicated.
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6710;
P2
This study is ongoing. And we look forward to demonstrating that neoadjuvant immunochemotherapy is expected to improve long-term survival of LA-HNSCC.
- Aqupla (nedaplatin) / Simcere
Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6690;
And we look forward to demonstrating that neoadjuvant immunochemotherapy is expected to improve long-term survival of LA-HNSCC. IC with nab-paclitaxel and nedaplatin showed promising efficacy and safety profile in locally advanced NPC.
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Outcomes of combined immunotherapy and palliative radiotherapy in patients with recurrent/metastatic head and neck cancers. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6670;
Prior radiotherapy might compromise patients' PFS. Increasing the number of immunotherapy cycles and combining with nab-paclitaxel chemotherapy may improve patient survival.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche
Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6586;
P2
Tislelizumab combined with nab-paclitaxel plus bevacizumab is effective with a manageable safety profile for EGFR-TKIs resistant NSCLC patients with ECOG ps 0-2. Clinical trial information: NCT04310943.
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Combining nimotuzumab with PD-L1 inhibitors and chemotherapy to treat esophageal cancer: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6532;
This combinational treatment regimen results in a significant improvement in OS compared to the combination of PD-L1 inhibitors and chemotherapy without increased AEs. Compared to other combinations of targeted drugs with PD-L1 inhibitors and chemotherapy, the use of nituzumab significantly prolonged mPFS and increased OS rates at 12 and 24 months.
- Tyvyt (sintilimab) / Eli Lilly
Sintilimab combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, multicenter, phase 2 trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6499;
P2
Compared to other combinations of targeted drugs with PD-L1 inhibitors and chemotherapy, the use of nituzumab significantly prolonged mPFS and increased OS rates at 12 and 24 months. Patients received concurrent thoracic radiotherapy (60
- narmafotinib (AMP945) / Amplia Therap
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6478;
P1/2
The trial will enrol up to 50 patients as part of the Phase 2 expansion cohort. Clinical trial information: NCT05355298.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin as a first line treatment for the management of metastatic pancreatic adenocarcinoma: A budget impact analysis from a U.S. payer perspective. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6475;
The model results indicate that the budget impact of NALIRIFOX may be minimal from a US health plan perspective. Given the poor prognosis of mPDAC, NALIRIFOX presents itself as an important new first line treatment option for people living with an aggressive and hard to treat cancer.
- Halaven (eribulin mesylate) / Eisai
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6224;
P
Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. Clinical trial information: NCT05953909.
- Hercessi (trastuzumab-strf) / Fosun Pharma, Intas, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6220;
The real-world data suggest similar efficacy and safety of HLX02 and RTZ plus pertuzumab with different chemotherapy regimens as the first-line treatment for patients with HER2-positive advanced breast cancer patients in China. Overall, the PFS was consistent with the CLEOPATRA trial in both groups, and there was no new safety signal.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6128;
No increase treatment-related side effects was reported. Thus, the combination of pyrotinib and taxanes or vinorelbine regimen can be an option for HER2-positive MBC.
- AiTan (rivoceranib) / HLB Bio Group
Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6121;
P1/2
The combination of apatinib and nab-paclitaxel showed promising antitumor activity in patients with metastatic TNBC as a second-line treatment, with a manageable safety profile. Clinical trial information: NCT05019690.
- Anniko (penpulimab) / Akesobio, Sino Biopharm
Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous cell: A phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5691;
P=N/A
Patients achieving profound tumor regression with neoadjuvant immunochemotherapy may present the possibility of safe surgical resection with reduced margins, enhancing organ preservation and minimizing surgical trauma. Clinical trial information: NCT05459415.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, AiRuiKa (camrelizumab) / HLB Bio Group
Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5690;
P2
These results meet protocol specifications for trial continuation. Final results will include long-term and stage 2 results.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5579;
P2
Based on the encouraging efficacy of our regimen in the first stage, we will continue the enrollment of patients in stage 2. Keywords: Esophageal squamous cell carcinoma; Envafolimab; Neoadjuvant therapy; Chemotherapy Clinical trial information: NCT05552651.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5479;
The efficacy of three-cycle regimen seems to be significantly better than the two-cycle regimen, which may indicate that the two-cycle neoadjuvant therapy is still insufficient, and confirmatory results need to be verified through large-scale clinical studies. Clinical trial information: ChiCTR2300068185.
- Tevimbra (tislelizumab-jsgr) / BeiGene
TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5469;
Exploratory analysis of correlative biomarkers suggests that KRAS ctDNA negative at baseline may be a pedictive markers benefit with treatments. Clinical trial information: ChiCTR2000040872.